ZYUS LIFE SCIENCES CORPORATION Financials ZYUS Life Sciences Corporation
Equities
ZYUS
CA9899601095
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.11 CAD | -5.13% |
|
+11.00% | +23.33% |
| 07/05 | ZYUS Life Sciences Corporation Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| 23/04 | ZYUS Life Sciences Receives US Patent for Pain Management Drug Candidate | MT |
Valuation
| Fiscal Period: December | 2023 | 2024 |
|---|---|---|
| Capitalization 1 | 62.86 | 78.64 |
| Enterprise Value (EV) 1 | 62.86 | 78.64 |
| P/E ratio | - | - |
| Yield | - | - |
| Capitalization / Revenue | 179 x | 184 x |
| EV / Revenue | 179 x | 184 x |
| EV / EBITDA | - | -3.97 x |
| EV / FCF | - | -13.8 x |
| FCF Yield | - | -7.25% |
| Price to Book | - | - |
| Nbr of stocks (in thousands) | 69,847 | 70,847 |
| Reference price 2 | 0.9000 | 1.110 |
| Announcement Date | 07/05/24 | - |
1CAD in Million2CAD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2023 | 2024 |
|---|---|---|
| Net sales 1 | 0.351 | 0.428 |
| EBITDA 1 | - | -19.8 |
| EBIT 1 | -19.37 | -17.2 |
| Operating Margin | -5,519.37% | -4,018.69% |
| Earnings before Tax (EBT) | - | - |
| Net income | - | - |
| Net margin | - | - |
| EPS | - | - |
| Free Cash Flow 1 | - | -5.7 |
| FCF margin | - | -1,331.78% |
| FCF Conversion (EBITDA) | - | - |
| FCF Conversion (Net income) | - | - |
| Dividend per Share | - | - |
| Announcement Date | 07/05/24 | - |
1CAD in Million
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | 0.077 | 0.099 | 0.097 | 0.101 | 0.105 | 0.109 | 0.113 |
| EBITDA 1 | - | -2.38 | -3.173 | - | -4.8 | -4.9 | -5 | -5.1 |
| EBIT 1 | - | -2.982 | -3.934 | -7.408 | -4.3 | -4.3 | -4.2 | -4.3 |
| Operating Margin | - | -3,872.73% | -3,973.74% | -7,637.11% | -4,257.43% | -4,095.24% | -3,853.21% | -3,805.31% |
| Earnings before Tax (EBT) | - | -12 | -4.214 | - | - | - | - | - |
| Net income | -4.681 | -11.97 | -4.193 | - | - | - | - | - |
| Net margin | - | -15,550.65% | -4,235.35% | - | - | - | - | - |
| EPS | -0.0900 | -0.2800 | -0.0600 | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 29/06/23 | 29/08/23 | 29/11/23 | 07/05/24 | - | - | - | - |
1CAD in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2023 | 2024 |
|---|---|---|
| Net Debt | - | - |
| Net Cash position | - | - |
| Leverage (Debt/EBITDA) | - | - |
| Free Cash Flow 1 | - | -5.7 |
| ROE (net income / shareholders' equity) | - | - |
| ROA (Net income/ Total Assets) | - | - |
| Assets | - | - |
| Book Value Per Share | - | - |
| Cash Flow per Share | - | - |
| Capex 1 | - | 0.05 |
| Capex / Sales | - | 11.68% |
| Announcement Date | 07/05/24 | - |
1CAD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
1.11
CAD
Average target price
2.75
CAD
Spread / Average Target
+147.75%
| 1st Jan change | Capi. | |
|---|---|---|
| +23.33% | 57.56M | |
| +17.96% | 44.96B | |
| +1.17% | 42.65B | |
| +48.77% | 41.85B | |
| -4.27% | 29.04B | |
| +11.42% | 26.08B | |
| -21.39% | 19.03B | |
| +4.86% | 12.75B | |
| +27.29% | 12.06B | |
| -3.50% | 11.75B |
- Stock Market
- Equities
- ZYUS Stock
- Financials ZYUS Life Sciences Corporation